您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > OTS964
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
OTS964
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
OTS964图片
CAS NO:1338542-14-5
规格:≥98%
包装与价格:
包装价格(元)
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)392.5
FormulaC23H24N2O2S
CAS No.1338542-14-5 (free base);
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 85 mg/mL (182.6 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
SMILES Code O=C1NC2=C(C(C3=CC=C([C@@H](C)CN(C)C)C=C3)=C(O)C=C2C)C4=C1SC=C4
Synonyms OTS964; OTS-964; OTS 964
实验参考方法
In Vitro

In vitro activity: OTS964 inhibits the growth of TOPK-positive cells with low IC50 values [A549 (31 nM), LU-99 (7.6 nM), DU4475 (53 nM), MDAMB- 231 (73 nM), T47D (72 nM), Daudi (25 nM), UM-UC-3 (32 nM), HCT-116 (33 nM),MKN1 (38 nM), MKN45 (39 nM), HepG2 (19 nM), MIAPaca-2 (30 nM), and 22Rv1 (50 nM)], whereas its growth inhibitory effect against TOPK-negative HT29 cancer cells is significantly weaker, with IC50 of 290nM. Although OTS964 reveals some suppressive effect on Src family kinases, the response to OTS964 in these cancer cells is not correlated with the expression of Src family kinases c-Src, Fyn, and Lyn, supporting the TOPK-dependent growth inhibitory effects of OTS964. Time lapse imaging in T47D cells shows that treatment with OTS964 induces cytokinesis defects followed by apoptosis.


Kinase Assay: OTS964, a dimethylated derivative of OTS514, is a potent and selective TOPK ((T-lymphokine-activated killer cell-originated protein kinase) inhibitor. It inhibits TOPK with high affinity and selectivity (IC50 value is 28 nM). TOPK is a protein that is found in a wide variety of cancers/tumors and is believed to work as an oncogene that promote tumor growth. Therefore, as an inhibitor of TOPK, OTS964 has potential anticancer activity. It causes a cytokinesis defect and the subsequent apoptosis of cancer cells in vitro as well as in xenograft models of human lung cancer.


Cell Assay: Cells (100 μl, A549 cells, LU-99 cells, DU4475 cells, MDA-MB-231 cells, T47D cells, Daudi cells, UM-UC-3 cells, HCT-116 cells, MKN1 cells, MKN45 cells, HepG2 cells, MIAPaca-2 cells, 22Rv1 cells and HT29 cells) are plated in 96-well plates at a certain density. The cells are allowed to adhere overnight before exposure to compounds for 72 hours at 37°C. Plates are read with a spectrophotometer at a wavelength of 450 nm. All assays are carried out in triplicate. After measuring IC50 values, we calculates the z scores to produce P values. After log transformation (base 10) of IC50 values (nM), the mean and SD are calculated for the log values of the IC50 for the 13 TOPK-positive cell lines.

In VivoAlthough administration of the free compound induces hematopoietic adverse reactions (leukocytopenia associated with thrombocytosis), the drug delivered in a liposomal formulation effectively causes complete regression of transplanted tumors without showing any adverse reactions in mice. Inhibition of TOPK activity with the liposomal OTS964 suppresses tumor growth through induction of cytokinesis defects and subsequent apoptosis. Although oral administration of OTS964 causes some hematopoietic toxicity, this is a transient effect. The spontaneous recovery from leukocytopenia is occured and the anticancer effectiveness of the oral drug is similar to that of the liposomal formulation, oral administration of the drug may prove to be more practical.
Animal modelBALB/cSLC-nu/nu mice
Formulation & DosageDissolved in 5% glucose; 40 mg/kg; i.v. injection.
ReferencesSci Transl Med. 2014 Oct 22;6(259):259ra145.